Eli Lilly has signed a licensing agreement worth $2.7 billion (approximately 4 trillion won) with a drug development company that leverages artificial intelligence (AI). This deal is seen as an example that highlights the growing demand for AI-driven drug development in the global pharmaceutical industry.


Lily Gateway Labs

Lily Gateway Labs

View original image

On March 29 (local time), Insilico Medicine, a drug development company listed in Hong Kong, announced that it has entered into a licensing and research agreement with Eli Lilly worth up to $2.75 billion.


Insilico Medicine will receive $115 million (approximately 168 billion won) as an upfront payment. The remaining amount will be paid in stages, depending on regulatory and commercial milestones. Eli Lilly has secured exclusive rights to develop, manufacture, and commercialize certain preclinical oral drug candidates discovered using Insilico's AI engine.


Insilico Medicine is a clinical-stage biotech company that utilizes generative AI and automation. The company went public on the Hong Kong Stock Exchange in December 2025.


This deal reflects the pharmaceutical industry's trend toward expanding the use of AI. In January this year, Eli Lilly announced the establishment of an "AI Collaborative Innovation Lab" in San Francisco with Nvidia and revealed plans to invest up to $1 billion over the next five years.



Additionally, last year, Eli Lilly signed a $345 million agreement with Alux, a subsidiary of China's XtalPi. At a conference, Lucas Montars, Eli Lilly's Chief Financial Officer (CFO), stated that the company is "making large-scale investments" in AI for research and development (R&D).


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing